Study of LP-184 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-06-09
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of
LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to
standard therapy or for whom no standard therapy is available. The secondary objectives are
to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity
of LP-184.